Skip to main content

Advertisement

SpringerLink
Log in

The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

To assess known cancer biomarkers CA-125, human tissue kallikreins KLK6 and KLK10, hemostatic markers and age with 5-year survival outcome from epithelial ovarian cancer.

Methods

Forty-one benign cyst cohorts and 83 patients diagnosed with ovarian cancer were recruited. The following assays were performed: fibrinogen, vWF antigen, d-dimer, ATIII activity, tPA, PAI-1, uPAR, KLK6, KLK10 and CA-125. Follow-up visits of cancer patients of more than 60 months were noted. Data between those who survived past 60 months and mortality from cancer were analyzed.

Results

Only 24 patients lived past 60 months, and 31 died (advanced stage n = 27). Those living past 60 months were significantly older and associated with similar pre-operative levels seen in benign cyst cohorts especially for KLK6, fibrinogen, vWF, AT levels despite upregulation of d-dimer, CA-125 and KLK10. Ovarian cancer cohorts living past 60 months were younger than those who died within 12 months (n = 12). Mortality within 12 months was associated with older age, upregulation of KLK6, fibrinogen, d-dimer, vWF, tPA antigen and reduced ATIII levels. Similarly, mortality within 36 months of disease showed older age with upregulation of CA-125, KLK6 d-dimer vWF antigen and tPA antigen levels. Late stage cancer (III/IV) showed upregulated CA-125, KLK6, KLK10, d-dimer and reduced AT compared to early stage cancer (I/II). The 5-year survival rate for early cancer was 80%, advanced 22.9% and overall 5-year survival rate was 43.6%.

Conclusion

Older age together with the novel biomarkers studied and their association with adverse outcome from epithelial ovarian cancer was seen especially within 12 and 36 months of disease. Those who lived past 60 months of disease showed similar pre-operative levels seen in benign cyst cohorts despite elevated d-dimer, CA125 and KLK 10. An enlarged study is needed to confirm these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schink JC (1999) Current initial therapy of stage III and IV ovarian cancer; challenges for managed care. Semin Oncol 26:2–7

    PubMed  CAS  Google Scholar 

  2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529

    Article  PubMed  CAS  Google Scholar 

  3. Bick RL (1992) Disseminated intravascular coagulation. Lab Med 23:161

    Google Scholar 

  4. Constantini V, Zacharaski L-R (1993) Fibrin and cancer. Thromb Haemost 69:406–414

    Google Scholar 

  5. Miyauchi S, Moroyama S, Moroyama T, Kyoizumi S, Asakawa J-I, Okamoto T, Takada K (1988) Malignant tumour cell lines produce intereleukin-1 like factor. In Vitro Cell Dev Biol 24:753–758

    Article  PubMed  CAS  Google Scholar 

  6. Kakkar AK, Chinswangwatanakul V, Tebutt S, Williamson RC (1995) Extrinsic pathway activation in cancer with high factor VIIa and tissue factor. Lancet 6:885–888

    CAS  Google Scholar 

  7. Koh CL Stephen, Tham K-F, Razvi-K, Oei PL, Lim FK, Roy AC, Parasad RNV (2001) Haemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost 7(2):141–148

  8. van Wersch JWJ, Peters C, Ubachs JMH (1995) Haemostasis in benign and malignant gynaecological tumors: a pilot study. Eur J Clin Chem Clin Biochem 33:225–229

    PubMed  Google Scholar 

  9. Von Tempelhof G-F, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L (1997) Blood coagulation and thrombosis in patients with ovarian cancer. Thromb Haemost 77:456–461

    Google Scholar 

  10. Borgfeldt C, Bendahl P-O, Ferno M, Casslen B (2003) High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer. Gynecol Oncol 91:112–117

    Article  PubMed  CAS  Google Scholar 

  11. Riisbro R, Stephens RW, Brunner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhof G-F (2001) Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 82:523–531

    Article  PubMed  CAS  Google Scholar 

  12. Beer JH, Haeberti A, Vogt A, Woodtli K, Henkel E, Furrer T, Fey MF (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745–749

    PubMed  CAS  Google Scholar 

  13. Stephen KohCL, Khalil R, Lim FK, Ilancheran A, Choolani M (2006) The association between fibrinogen, von Willebrand Factor, antithrombin III and d-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 12:3–8

    Article  Google Scholar 

  14. Duffy MJ (1995) Proteases as prognostic markers in cancer. Clin Cancer Res 2:613–618

    Google Scholar 

  15. Diamandis EP, Yousef GM (2002) Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 48:1198–1205

    PubMed  CAS  Google Scholar 

  16. Diamandis EP, Scorilas A, Fracchioli S et al (2003) Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 21(6):1035–1043

    Article  PubMed  CAS  Google Scholar 

  17. Obiezu CV, Diamandis EP (2005) Human tissue kallikrein gene family: applications in cancer. Cancer Lett 224(1):1–22

    Article  PubMed  CAS  Google Scholar 

  18. Borgono CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmafeldt B, Schmitt M, Diamandis EP (2006) Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res 12:1487–1493

    Article  PubMed  CAS  Google Scholar 

  19. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function and association to disease. Endocr Rev 22:184–204

    Article  PubMed  CAS  Google Scholar 

  20. Diamandis EP, Okui A, Mitsui S, Luo L-Y, Soosaipillai A, Grass L, Nakamura T, Howarth JC, Yamaguchi N (2002) Human kallikrein 11: a new biomarker of prostate and ovarian cancer. Cancer Res 62:295–300

    PubMed  CAS  Google Scholar 

  21. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998) CA-125, the past and the future. Int J Biol Markers 13:179–187

    PubMed  CAS  Google Scholar 

  22. Mills GB, Bast RC, Srivastava S (2001) Future for ovarian cancer screening, novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst (Bethesda) 93:1437–1439

    CAS  Google Scholar 

  23. Koh SCL, Yuen R, Viegas OAC, Chua SE, Ng BL, Sen DK, Ratnam SS (1989) A plasmin generation method for the determination of t-PA activity in blood. Immunol Cell Biol 67:197–203

    Article  PubMed  CAS  Google Scholar 

  24. Koh SCL, Yuen R, Viegas OAC, Chua SE, Ng BL, Sen DK, Ratnam SS (1989) Plasma tissue plasminogen activator inhibitor (t-PAI) activity in normal subjects. Med Sci Res 17:135–136

    CAS  Google Scholar 

  25. Gaducci A, Baicchhi U, Marrai R et al (1996) Preoperative evaluation of d-dimer and CA-125 levels to differentiate benign from malignant ovarian masses. Gynecol Oncol 60:197–202

    Article  Google Scholar 

  26. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91:869–874

    Article  PubMed  CAS  Google Scholar 

  27. Fernebro E, Madsen RR, Ferno M, Brunner N, Bendahl N, Bendahl P, Christensen IJ, Johnson A, Nilbert M (2001) Prognostic importance of the soluble plasminogen activator receptor, suPAR in plasma from rectal cancer patients. Eur J Cancer 37:486–491

    Article  PubMed  CAS  Google Scholar 

  28. Koh CLS, Sahil F, Lutan D, Siddik D, Suwiyoga K, Budiana G, Pradjatmo H, Saleh AZ, Aziz MF, Winarto H, Narasimhan K, Ilancheran A, Razvi K, Choolani M (2009) Systemic ovarian cancer biomarkers in Indonesian women with ovarian tumours Systemic ovarian cancer biomarkers in Indonesian women with ovarian tumours. Abstract 38, The 7th Singapore international congress of O&G, 26–29 August 2009, Singapore

  29. Kramer BS, Gohagar J, Prorok PC, Smart C (1993). A national cancer institute sponsored screening trial for prostatic, lung, colorectal and ovarian cancers. Cancer Suppl 71:589–593

    Google Scholar 

  30. Bjorge T, Engeland A, Hansen S, Trope CG (1998) Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 75:663–670

    Article  PubMed  CAS  Google Scholar 

  31. Luo L-Y, Katsaros D, Scorilas A, Francchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman U-H, Massobrio M, van de Zee AGJ, Vergote I, Diamandis EP (2003) The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 63:807–811

    PubMed  CAS  Google Scholar 

  32. Razvi K, Koh, SCL, Loganath A, Narasimhan K, Ilancheran A, Choolani M (2005) Human tissue kallikreins, hK6, hK10 as novel biomarkers for epithelial ovarian cancer. J Thromb Haemost 5(Suppl 2) (abstract)

  33. Ni X, Zhang W, Huang K-C, Wang Y, Ng S-K, Mok SC, Berkowitz RS, Ng S-W (2004) Characterization of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91:725–731

    PubMed  CAS  Google Scholar 

  34. Luo L-Y, Bunting P, Scorilas A, Diamandis EP (2001) Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta 306:111–118

    Article  PubMed  CAS  Google Scholar 

  35. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Gershenson DM, Schmandt R (2003) Over expression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90:44–50

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The study was made possible through the support from the National Medical Research Council Grant NMRC/0154/1996, University Department of Obstetrics and Gynaecology and the Lee Foundation. The expert technical assistance from Chua SE, Yuen WK and Ng BL is gratefully acknowledged.

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, National University Health Systems (NUHS), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore

    Stephen C. L. Koh, K. Narasimhan, A. Ilancheran, J. J. Low & M. Choolani

  2. Southend University Hospital, NHS Foundation Trust, Essex, UK

    K. Razvi

  3. Department of Biostatistics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore

    Y. H. Chan

Authors
  1. Stephen C. L. Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Razvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. H. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Narasimhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Ilancheran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. J. Low
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Choolani
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Ovarian Cancer Research Consortium of SE Asia

Corresponding author

Correspondence to Stephen C. L. Koh.

Additional information

The members of The Ovarian Cancer Research Consortium of SE Asia are given in Appendix.

Appendix: The Ovarian Cancer Research Consortium of SE Asia

Appendix: The Ovarian Cancer Research Consortium of SE Asia

Department of Obstetrics and Gynaecology, Adam Malik Hospital, University of Sumatera Utara, Medan, Indonesia: Sahil F, Lutan D, Siddik D; Department of Obstetrics and Gynaecology, Sanglah Denpasar Hospital, Udayana University, Denpasar, Indonesia: Suwiyoga K, Budiana G; Department of Obstetrics and Gynaecology, Sardjito Hospital, Gadja Mada University, Yogyakarta, Indonesia: Pradjitmo H; Department of Obstetrics and Gynaecology, Dr Mhd Hoesin General Hospital, University of Sriwijaya, Palembang, Indonesia: Saleh AZ; Department of Obstetrics and Gynaecology, Dr Cipto Mangukusumo Hospital, University of Indonesia: Aziz MF, Winarto H; Department of Obstetrics and Gynaecology, Tu Du Hospital, Ho Chin Minh City, Vietnam: Thanh PV, Hoan NKH; Department of Obstetrics and Gynaecology, Sultanah Aminah Hosiptal, Johor Bahru, Malaysia: Ravichandran I, Dominic N.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koh, S.C.L., Razvi, K., Chan, Y.H. et al. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet 284, 183–190 (2011). https://doi.org/10.1007/s00404-010-1605-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-010-1605-z

Keywords

Search

Navigation